Disposition and Pharmacokinetics of a GalNAc3-Conjugated Antisense Oligonucleotide Targeting Human Lipoprotein (a) in Monkeys.

MLA

Yu, Rosie Z., et al. “Disposition and Pharmacokinetics of a GalNAc3-Conjugated Antisense Oligonucleotide Targeting Human Lipoprotein (a) in Monkeys.” Nucleic Acid Therapeutics, vol. 26, no. 6, Dec. 2016, pp. 372–80. EBSCOhost, https://doi.org/10.1089/nat.2016.0623.

APA

Yu, R. Z., Gunawan, R., Post, N., Zanardi, T., Hall, S., Burkey, J., Kim, T.-W., Graham, M. J., Prakash, T. P., Seth, P. P., Swayze, E. E., Geary, R. S., Henry, S. P., & Wang, Y. (2016). Disposition and Pharmacokinetics of a GalNAc3-Conjugated Antisense Oligonucleotide Targeting Human Lipoprotein (a) in Monkeys. Nucleic Acid Therapeutics, 26(6), 372–380. https://doi.org/10.1089/nat.2016.0623

Chicago

Yu, Rosie Z, Rudy Gunawan, Noah Post, Thomas Zanardi, Shannon Hall, Jennifer Burkey, Tae-Won Kim, et al. 2016. “Disposition and Pharmacokinetics of a GalNAc3-Conjugated Antisense Oligonucleotide Targeting Human Lipoprotein (a) in Monkeys.” Nucleic Acid Therapeutics 26 (6): 372–80. doi:10.1089/nat.2016.0623.